Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of SYS6043 with PD-1/PD-L1 inhibitor with or without chemotherapy in advanced solid tumors
CTR20254604Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SYS6043 in small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), non-small cell lung cancer (NSCLC), Nonhematologic neoplasms, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Dec 2025; status: active.
02
Drugs
SYS6043
03
Conditions
small cell lung cancer (SCLC)nasopharyngeal carcinoma (NPC)non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254604.